Loading...
•
Mar 31, 2024
Celldex Q1 2024 Earnings Report
Reported financial results with a net loss for the first quarter of 2024.
Key Takeaways
Celldex Therapeutics reported its Q1 2024 financial results, with a revenue of $0.2 million and a net loss of $32.8 million. The company's cash position is strong at $823.8 million, expected to fund operations through 2027.
Cash, cash equivalents and marketable securities totaled $823.8 million as of March 31, 2024.
Total revenue was $0.2 million in the first quarter of 2024.
Research and development expenses were $31.7 million in the first quarter of 2024.
Net loss was $32.8 million, or ($0.56) per share, for the first quarter of 2024.
Revenue by Segment
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at March 31, 2024 are sufficient to meet estimated working capital requirements and fund current planned operations through 2027.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...